Unknown

Dataset Information

0

Selective disruption of an oncogenic mutant allele by CRISPR/Cas9 induces efficient tumor regression.


ABSTRACT: Approximately 15% of non-small cell lung cancer cases are associated with a mutation in the epidermal growth factor receptor (EGFR) gene, which plays a critical role in tumor progression. With the goal of treating mutated EGFR-mediated lung cancer, we demonstrate the use of clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9) system to discriminate between the oncogenic mutant and wild-type EGFR alleles and eliminate the carcinogenic mutant EGFR allele with high accuracy. We targeted an EGFR oncogene harboring a single-nucleotide missense mutation (CTG > CGG) that generates a protospacer-adjacent motif sequence recognized by the CRISPR/Cas9 derived from Streptococcus pyogenes. Co-delivery of Cas9 and an EGFR mutation-specific single-guide RNA via adenovirus resulted in precise disruption at the oncogenic mutation site with high specificity. Furthermore, this CRISPR/Cas9-mediated mutant allele disruption led to significantly enhanced cancer cell killing and reduced tumor size in a xenograft mouse model of human lung cancer. Taken together, these results indicate that targeting an oncogenic mutation using CRISPR/Cas9 offers a powerful surgical strategy to disrupt oncogenic mutations to treat cancers; similar strategies could be used to treat other mutation-associated diseases.

SUBMITTER: Koo T 

PROVIDER: S-EPMC5570104 | biostudies-literature | 2017 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

Selective disruption of an oncogenic mutant allele by CRISPR/Cas9 induces efficient tumor regression.

Koo Taeyoung T   Yoon A-Rum AR   Cho Hee-Yeon HY   Bae Sangsu S   Yun Chae-Ok CO   Kim Jin-Soo JS  

Nucleic acids research 20170701 13


Approximately 15% of non-small cell lung cancer cases are associated with a mutation in the epidermal growth factor receptor (EGFR) gene, which plays a critical role in tumor progression. With the goal of treating mutated EGFR-mediated lung cancer, we demonstrate the use of clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9) system to discriminate between the oncogenic mutant and wild-type EGFR alleles and eliminate the carcinogenic mutant EGFR a  ...[more]

Similar Datasets

| S-EPMC7163449 | biostudies-literature
| S-EPMC7270506 | biostudies-literature
| S-EPMC6082849 | biostudies-other
| S-EPMC5363210 | biostudies-literature
| S-EPMC4030483 | biostudies-literature
| S-EPMC4490936 | biostudies-literature
| S-EPMC6005869 | biostudies-literature
| S-EPMC11018756 | biostudies-literature
| S-EPMC4730182 | biostudies-literature
| S-EPMC7292542 | biostudies-literature